Perioperative Nivolumab in Resectable Lung Cancer
- Tina Cascone*
- , Mark M. Awad
- , Jonathan D. Spicer
- , CheckMate 77T Investigators
- , Jie He
- , Shun Lu
- , Boris Sepesi
- , Fumihiro Tanaka
- , Janis M. Taube
- , Robin Cornelissen
- , Libor Havel
- , Nina Karaseva
- , Jaroslaw Kuzdzal
- , Lubos B. Petruzelka
- , Lin Wu
- , Jean Louis Pujol
- , Hiroyuki Ito
- , Tudor Eliade Ciuleanu
- , Ludmila De Oliveira Muniz Koch
- , Annelies Janssens
*Corresponding author for this work
- University of Texas MD Anderson Cancer Center
- Dana-Farber Cancer Institute
- McGill University Health Centre
- Chinese Academy of Medical Sciences
- Shanghai Jiao Tong University
- University of Occupational and Environmental Health, Japan
- Johns Hopkins University
- Thomayer Hospital
- St. Petersburg State Budgetary Healthcare Institution
- Jagiellonian University Medical College
- Charles University
- Central South University
- CHU Montpellier
- Kanagawa Cancer Center Research Institute
- Iuliu Hatieganu University of Medicine and Pharmacy
- Antwerp University Hospital
- Oncology Institute Professor Doctor Alexandru Trestioreanu
- Universitätsklinikum Schleswig-Holstein
- Center For Specialized Types Of Medical Care
- Saitama Cancer Center
- Hospital Israelita Albert Einstein
- A Bristol-Myers Squibb Company
- University Hospital Puerta de Hierro-Majadahonda
Research output: Contribution to journal › Article › Academic › peer-review
420
Citations
(Scopus)
115
Downloads
(Pure)